Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer
Conclusions: First- or second-line afatinib demonstrated preliminary activity and manageable safety in EGFR FISH-positive patients with advanced non–small-cell lung cancer.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Original Articles Source Type: research
More News: Acne | Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Lung Cancer | Oral Cancer | Study